Dorzolamide suppresses PKCδ -TIRAP-p38 MAPK signaling axis to dampen the inflammatory response

Author:

Rajpoot Sajjan1ORCID,Kumar Ashutosh2,Gaponenko Vadim3,Thurston Teresa LM4,Mehta Dolly5,Faisal Syed M6,Zhang Kam YJ2,Jha Hem C1,Darwhekar Gajanan N7,Baig Mirza S1ORCID

Affiliation:

1. Department of Biosciences & Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Indore, 453552, India

2. Laboratory for Structural Bioinformatics, Center for Biosystems Dynamics Research, RIKEN, Tsurumi, Yokohama, Kanagawa, 230-0045, Japan

3. Department of Biochemistry & Molecular Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA

4. MRC Centre for Molecular Bacteriology & Infection, Imperial College London, London, SW7 2AZ, UK

5. Department of Pharmacology & Center for Lung & Vascular Biology, College of Medicine, The University of Illinois, Chicago, IL 60612, USA

6. National Institute of Animal Biotechnology, Hyderabad, 500032, India

7. Acropolis Institute of Pharmaceutical Education & Research, Indore, 453771, India

Abstract

Background: Sepsis is a syndrome due to microbial infection causing impaired multiorgan function. Its underlying cause is immune dysfunction and macrophages play an essential role. Methods: TIRAP interaction with PKCδ in macrophage was studied, revealing downstream signaling by Western blot and quantitative reverse transcriptase PCR. Dorzolamide (DZD) disrupting TIRAP–PKCδ interaction was identified by virtual screening and validated in vitro and in septic mice. Results: The study highlights the indispensable role of TIRAP–PKCδ in p38 MAPK-activation, NF-κB- and AP-1-mediated proinflammatory cytokines expression, whereas DZD significantly attenuated the signaling. Conclusion: Targeting TIRAP–PKCδ interaction by DZD is a novel therapeutic approach for treating sepsis.

Funder

Indian Institute of Technology Indore

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3